BCL2 and ovarian cancer: In addition, the competitive inhibitor Navitoclax (ABT-263) shows promise in inhibiting Bcl-XL and Bcl-2 by mimicking the BH3 domain of Bad, and multiple studies have illustrated its ability to decrease overall cell survival and reduce chemoresistance in ovarian cancer [229,230,231,233].